3,4-diarylpyrazoles and their use in the therapy of cancer

Details 3,4-diarylpyrazoles and their use in the therapy of cancer 3,4-diarylpyrazoles and their use in the therapy of cancer

2007-07-24

2007-07-24

Saeed, Kamal A. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S373100, C548S377100

Reexamination Certificate

active

10499030

ABSTRACT:
The present invention pertains to the use of certain 3,4-diarylpyazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3is independently: a C5-20aryl group, and is optionally substituted; Ar4is independently: a C5-20aryl group, and is optionally substituted; R5is independently: hydrogen; halo; hydroxyl; ether; formyl; acyl; carboxy; ester; acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamide; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N</SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to such compounds, pharmaceutical compositions comprising such compounds, such compounds for medical use, such compounds use in the treatment of conditions mediated by HSP90, including, for example, cancer, and use of such compounds in the preparation of medicaments for such treatments.

REFERENCES:
patent: WO 95 31451 (1995-11-01), None
patent: WO 96 03385 (1996-02-01), None
patent: WO 98 52937 (1998-11-01), None
patent: WO 00 07996 (2000-02-01), None
patent: WO 00 19994 (2000-04-01), None
patent: WO 02 062804 (2002-08-01), None
patent: WO 02 066462 (2002-08-01), None
patent: WO 02 092593 (2002-11-01), None
Ohsumi et al.: “Syntheses and antitumor activity of cisrestricted combretastatins: 5-membered heterocyclic analogs”; Bioorganic & Medicinal Chemistry Letters; vol. 8, No. 22; pp. 3153-3158; XP002235812.
Penning et al.: “3,4-Diarylpyrazoles: potent and selective inhibitors of cyclooxygenase-2”; Bioorganic & Medicinal Chemistry Letters; vol. 7, No. 16; 1997; pp. 2121-2124; XP002235813.
Bannier et al.: “Determination of a new anti-inflammatory agent, 1-isobutyl-3,4-diphenyl-pyrazole-5-acetic acid, by high-performance liquid chromatography”; Journal of Chromatograph; vol. 227, No. 1, 1982, pp. 213-218; XP009008354.
Meanwell et al.: “Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic”; Journal of Medicinal Chemistry; vol. 35, No. 2; 1992; pp. 389-397; XP002235815.
DATABASE WPI; Section Ch, Week 200312; Derwent Publications Ltd.; AN 2003-129155; XP002235817.
DATABASE CA ′Online!; Chemical Abstracts Service; Khilya et al.: “Synthetic and modified isoflavonoids. XV. Reaction of synthetic isoflavone analogs with hydrazine hydrate derivatives”; retrieved from STN; Database accession No. 124:8437 CA; XP002235816; & Khimiy a Prirodnykh Soedinenii (1994), (5), 629-33, 1994.

Affiliated with

Also associated with

Rating

3,4-diarylpyrazoles and their use in the therapy of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3,4-diarylpyrazoles and their use in the therapy of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-diarylpyrazoles and their use in the therapy of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3736415